Brain Tumor Drug Discovery Services

Creative Biolabs provides integrated brain tumor drug discovery services for programs that need to validate a target, identify or rank therapeutic candidates, understand resistance, evaluate combinations, establish response biomarkers, or build an efficacy and exposure package for lead progression. We support glioblastoma and other project-defined primary or metastatic brain tumor studies using fit-for-purpose biochemical, cell-based, 3D, organoid, microphysiological, ex vivo, and in vivo models.

Build the Program Around the Development Decision

Brain tumors create a demanding discovery setting: disease-relevant molecular states coexist with strong intratumoral heterogeneity, invasive behavior, therapy-induced plasticity, a specialized neural microenvironment, and variable access across the blood-brain barrier. A useful discovery plan therefore links tumor biology, compound exposure, and the intended translational claim. We first define what must be demonstrated and then choose the minimum model complexity that can answer that question reliably.

Typical programs are designed around one or more of the following decisions:

• Target validation: Determine whether genetic or pharmacological perturbation changes tumor-cell survival, proliferation, stem-like state, invasion, or a project-specific pathway in models with the relevant molecular background.
• Hit discovery and ranking: Screen libraries or focused panels, confirm concentration-dependent activity, counter-screen for nonspecific toxicity, and prioritize compounds using predefined potency, efficacy, selectivity, and developability criteria.
• Resistance and recurrence: Compare treatment-naïve and resistant states, evaluate adaptive signaling or cell-state shifts, and test rational combinations intended to delay or reverse escape.
• Precision response: Measure inter-model or patient-derived response differences and connect pharmacological phenotypes with genomic, transcriptomic, proteomic, or imaging biomarkers.
• Brain delivery: Determine whether insufficient effect reflects limited permeability, active efflux, protein binding, metabolic instability, inadequate free exposure, or true biological inactivity.
• Translational progression: Confirm a selected candidate in orthogonal human-relevant and in vivo systems while aligning pharmacokinetics, pharmacodynamics, tolerability, and efficacy.

Programs can integrate our Glioblastoma Drug Discovery Service, Phenotypic Screening Services, and Mechanism of Action (MOA) Studies when the central need is a tumor-specific screen followed by mechanistic confirmation.

Select Models That Preserve Brain Tumor Biology

Model selection is based on tumor type and molecular context, the mechanism under study, the required throughput, and the endpoint that will drive the decision. A broad primary screen may favor a reproducible cell-based system; a later-stage claim about invasion, microenvironmental response, or delivery may require a 3D, organoid, chip, slice, or in vivo model. Whenever possible, the progression plan preserves the same biological question across models so that changes in outcome can be interpreted rather than merely observed.

Tumor-Intrinsic Models

Tumor-intrinsic studies may use established lines, engineered isogenic pairs, patient-derived cultures, glioma stem-like cells, neurospheres, or organoids. The selected panel is matched to project variables such as driver alteration, lineage, grade, treatment history, MGMT promoter status, IDH status, receptor or pathway dependence, and known resistance phenotype. Controls may include nonmalignant neural or glial cells, target-negative tumor cells, rescue conditions, inactive analogs, or genetic confirmation of a pharmacological result.

For spatially organized studies, our Brain Tumor Organoid Modeling Service can support organoid establishment, characterization, drug-response testing, and imaging-based analysis. Organoids are introduced when their preservation of heterogeneity, architecture, or cell-state diversity is necessary for the study claim, not simply as a later-stage label.

Microenvironment, Invasion, and Delivery Models

Brain tumor behavior can be evaluated in the presence of astrocytes, microglia, neurons, endothelial cells, pericytes, immune populations, or a defined extracellular matrix. Co-culture and compartmentalized systems are useful for separating tumor-cell-autonomous activity from effects driven by inflammatory signaling, vascular contact, neural guidance, or matrix-dependent invasion. A perfused or BBB-coupled design can further connect vascular dosing with tumor-compartment exposure and response.

Related options include the Brain-On-A-Chip Platform for microphysiological model development and the Ex Vivo Brain Slice Assay for short-term tissue-context validation. Model feasibility, specimen availability, biosafety, and endpoint access are reviewed before execution.

Connect Perturbation, Exposure, and Response

A screening campaign is designed as a connected sequence rather than a single viability readout. Assay development establishes the biological state, dynamic range, control behavior, timing, and technical variability. The primary screen identifies active conditions; confirmation then tests reproducibility, concentration response, selectivity, and assay interference. Orthogonal and mechanistic studies determine whether a confirmed phenotype arises from the intended biology, while exposure studies assess whether the relevant concentration can be achieved in the brain or tumor compartment.

Screening Formats and Perturbations

• Small molecules and repurposing panels: Focused or broad libraries can be tested in single-dose, multi-dose, matrixed, or staged formats, with plate maps and QC criteria defined before screening.
• Biologics and advanced modalities: Where model access and delivery are compatible, studies may evaluate antibodies, peptides, oligonucleotides, viral or nonviral genetic tools, cell-directed agents, or project-specific modalities.
• Genetic validation: Knockdown, knockout, overexpression, rescue, or isogenic comparison can test target dependence and help distinguish on-target biology from compound-specific effects.
• Combination and sequence studies: Candidates can be paired with project-defined standards, radiation-mimetic or irradiation conditions, pathway inhibitors, or immune-modulating interventions. Simultaneous and sequential schedules can be compared when timing may alter response.
• Stress and resistance conditions: Hypoxia, nutrient limitation, treatment adaptation, extracellular matrix, inflammatory cues, or resistant derivatives can be introduced to test whether activity persists beyond a permissive baseline.

Combination Design and Analysis

Combination studies begin with single-agent response ranges and a defined biological rationale. A checkerboard or reduced matrix can compare dose pairs, while fixed-ratio or sequential designs may be more efficient for established hypotheses. Analysis can include response-surface visualization and project-agreed reference models such as Bliss independence, Loewe additivity, highest single agent, or ZIP. A numerical synergy score is interpreted together with replicate quality, achievable exposure, schedule, and evidence that the combination does not simply increase general toxicity.

Higher-scale campaigns can use our High-Throughput Screening Platform, while mechanism-focused follow-up can be coordinated through Biomarker Analysis and MOA studies. The same controls and response definitions are retained across the progression wherever technically possible.

Build an Orthogonal Evidence Package

A strong hit is supported by multiple measurements that answer different failure modes. Viability alone may conflate cytostasis, cell death, assay interference, and altered metabolism. Conversely, a pathway biomarker can change without producing a durable tumor phenotype. We therefore pair the decision-driving endpoint with orthogonal evidence chosen for the mechanism and model.

• Growth and survival: Cell count, ATP or metabolic viability, membrane integrity, apoptosis, proliferation, clonogenic recovery, sphere formation, and regrowth after washout.
• Cell state and differentiation: Stemness-associated markers, lineage programs, mesenchymal or proneural features, stress states, senescence, and project-defined transcriptional or protein signatures.
• Invasion and migration: Live-cell tracking, radial invasion, matrix penetration, trans-compartment migration, axon-guided movement, and spatial quantification within 3D tissues.
• Target engagement and signaling: Direct engagement where feasible, phosphorylation, pathway reporters, protein localization, degradation, downstream transcription, rescue, and temporal pharmacodynamics.
• Microenvironmental response: Astrocyte or microglial activation, cytokines, immune-cell recruitment or cytotoxicity, endothelial interaction, vascular permeability, and spatial tumor-host effects.
• Imaging and histology: High-content morphology, multiplex immunofluorescence, tumor burden, necrosis, proliferation, apoptosis, invasion margins, vascular markers, and tissue distribution.
• Molecular profiling: Targeted panels or project-defined transcriptomic, proteomic, metabolomic, or genomic measurements for mechanism, stratification, resistance, and pharmacodynamic biomarker selection.

Analysis plans specify normalization, replicate structure, outlier handling, curve fitting, multiple-comparison strategy, acceptance ranges, and decision thresholds before the final dataset is interpreted. Results are reported with assay performance metrics, raw and processed data, representative images, statistical outputs, and a statement of limitations. Negative results are separated into inadequate exposure, model nonqualification, absence of target dependence, and lack of pharmacological activity whenever the evidence permits.

Related Research

The following studies are directly relevant to brain tumor drug discovery.

Patient-Derived GBM Spheroids Enable Combination Response Testing on a Microfluidic Chip

Akay and colleagues cultured cells derived from three human glioblastoma specimens as 3D spheroids in a seven-channel brain cancer chip. The device generated relative gradients of temozolomide and bevacizumab while diffusion-prevention gaps reduced cross-channel interference. Spheroid imaging and endpoint viability showed patient-to-patient differences, and the combination produced greater cell death than either single treatment across the tested samples, although the strength of the comparison varied by patient. The study demonstrates why controlled exposure, 3D culture, multiple specimens, and quantitative confirmation should be designed together for combination assessment.

Fig. 1 Patient-derived GBM spheroids across microfluidic drug-gradient channels before and after temozolomide and bevacizumab exposure.^1,3

A Neural Spheroid Co-Culture Provides a Quantifiable Anti-Infiltration Screen

Tsang and colleagues combined patient-derived glioblastoma cells with human iPSC-derived cortical neural spheroids that extended axons. High-content imaging and automated analysis quantified migration and infiltration over time. In a pilot panel of pathway and motility inhibitors, the two GBM lines showed different inhibitor sensitivities: GBM20 infiltration was reduced by a FAK inhibitor, whereas GBM1 responded to the CXCR4 antagonist motixafortide. The work shows how a microenvironment-relevant phenotype can reveal line-specific therapeutic responses and supports including invasion or infiltration endpoints when tumor control cannot be represented adequately by cell survival alone.

Fig. 2 Pilot anti-infiltration screen in patient-derived GBM cell and human neural spheroid co-cultures.^2,3

Frequently Asked Questions

1. What is included in Creative Biolabs' brain tumor drug discovery services?

   Services can include target validation, model selection and qualification, assay development, focused or high-throughput screening, hit confirmation, dose-response and combination studies, mechanism-of-action work, biomarker analysis, ADME/DMPK, brain and tumor exposure assessment, ex vivo or in vivo efficacy testing, histology, data analysis, and reporting. The final scope is selected for the development decision and modality.

2. Which brain tumor types can be studied?

   Programs can be designed for glioblastoma and other project-defined primary or metastatic brain tumors when suitable models, specimens, and endpoints are available. Model selection considers tumor lineage, grade, molecular drivers, treatment history, resistance state, and the translational question. Feasibility is confirmed before the study begins.

3. Can patient-derived brain tumor cells or organoids be used?

   Yes. Depending on availability and project requirements, studies can use patient-derived cells, glioma stem-like cultures, neurospheres, organoids, or explant-related models. Source, passage, identity, baseline phenotype, growth characteristics, and assay suitability are documented, and multiple models may be used to evaluate response heterogeneity.

4. Do you support high-throughput and phenotypic screening?

   Yes. Screening can use target-based or phenotypic formats, including viability, proliferation, apoptosis, morphology, invasion, migration, sphere formation, pathway reporters, and high-content imaging. Throughput is matched to model complexity: broad discovery may start in a scalable model and progress into 3D, organoid, chip, slice, or in vivo confirmation.

5. Can you test drug combinations and resistance mechanisms?

   Yes. We can compare simultaneous or sequential combinations, generate dose matrices, and apply a project-agreed additivity or synergy model. Resistant derivatives, treatment-adapted states, patient-derived models, genetic perturbations, biomarker assays, and temporal pathway measurements can be used to investigate escape mechanisms and rational combination strategies.

6. How do you address blood-brain barrier penetration and brain exposure?

   A program may combine in vitro permeability or transporter studies, ADME/DMPK, protein binding, brain or tumor concentration measurements, and BBB-coupled microphysiological models. Exposure is compared with the active concentration range so that inadequate delivery can be distinguished from lack of target biology or intrinsic tumor resistance.

7. What controls and quality criteria are used?

   Controls are selected for the assay and can include vehicle, positive and negative pharmacological controls, target-negative cells, nonmalignant neural cells, genetic controls, inactive analogs, rescue conditions, and baseline model qualification. Assay window, variability, replicate acceptance, plate or batch effects, curve quality, and predefined advancement thresholds are reviewed before interpretation.

8. What information is needed to start a brain tumor drug discovery project?

   Helpful inputs include the tumor type and molecular context, target or therapeutic hypothesis, test-article modality, available compounds or biological materials, preferred models, prior data, vehicle and concentration constraints, desired endpoints, throughput, timeline, and the decision the results must support. If the model or assay is not established, a feasibility phase can define the operating window.

References

1. Akay, Metin, et al. "Drug Screening of Human GBM Spheroids in Brain Cancer Chip." Scientific Reports, vol. 8, 2018, article 15423. https://doi.org/10.1038/s41598-018-33641-2
2. Tsang, Victoria S. K., et al. "A Human iPSC-Based Neural Spheroid Platform for Modelling Glioblastoma Infiltration Using High-Content Imaging." Scientific Reports, vol. 16, 2026, article 1223. https://doi.org/10.1038/s41598-025-30914-5
3. Distributed under Open Access license CC BY 4.0, without modification.